Edition:
United States

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

3.62USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
170,836
52-wk High
$5.25
52-wk Low
$1.93

Latest Key Developments (Source: Significant Developments)

Cerus Corp reports Q3 loss per share $0.12
Thursday, 2 Nov 2017 04:01pm EDT 

Nov 2 (Reuters) - Cerus Corp :Cerus Corp reports third quarter 2017 results.Q3 loss per share $0.12.Q3 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.Cerus Corp - ‍product revenue for q3 of 2017 was $10.8 million, up 6 pct compared to $10.2 million recognized during same period in 2016​.  Full Article

Cerus and Kedrion Biopharma enter distribution agreement for full INTERCEPT blood system portfolio
Tuesday, 31 Oct 2017 08:30am EDT 

Oct 31 (Reuters) - Cerus Corp :Cerus and Kedrion Biopharma enter distribution agreement for the full INTERCEPT blood system portfolio in Italy.Says ‍entered into an agreement with Kedrion Biopharma to distribute full complement of INTERCEPT blood system products in italy​.Says ‍Kedrion Biopharma will be sole distributor for intercept blood systems in Italy​.Says ‍kedrion Biopharma will have right to distribute INTERCEPT red blood cells following CE mark approval​.  Full Article

Cerus announces agreement with transfusion Center of the Community of Madrid
Monday, 30 Oct 2017 08:30am EDT 

Oct 30 (Reuters) - Cerus Corp :Cerus announces agreement with transfusion Center of the Community of Madrid.Entered into a supply agreement with Centro de transfusión de la Comunidad de Madrid (CTCM) for intercept blood system for platelets​.  Full Article

Cerus Corp files for mixed shelf of up to $250 mln - SEC filing‍​
Friday, 4 Aug 2017 05:20pm EDT 

Aug 4 (Reuters) - Cerus Corp :Cerus Corp files for mixed shelf of up to $250 million - SEC filing‍​.  Full Article

Cerus Q2 loss per share $0.16
Thursday, 3 Aug 2017 04:02pm EDT 

Aug 3 (Reuters) - Cerus Corp :Cerus Corporation reports second quarter 2017 results.Q2 loss per share $0.16.Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Cerus Corp- ‍product revenue for Q2 of 2017 was $9.5 million, up 3%​.Cerus Corp- ‍expect 2017 product revenue to be in range of $40 to $46 million​.FY2017 revenue view $41.2 million -- Thomson Reuters I/B/E/S.  Full Article

Cerus enters into $40 mln amended growth capital agreement
Wednesday, 2 Aug 2017 08:30am EDT 

Aug 2 (Reuters) - Cerus Corp :Cerus enters into $40 million amended growth capital agreement.Cerus Corp - it has entered into a $40 million amended growth capital credit facility with oxford finance llc.Cerus Corp - under amended facility, cerus received an immediate $30 million loan at closing on july 31, 2017.Cerus Corp - has option to draw another $10 million subject to achieving a specified revenue milestone.Cerus Corp - a portion of proceeds from initial $30 million loan were used to repay outstanding term loans of about $17.6 million.  Full Article

Cerus expands agreement with French National Blood Service
Tuesday, 1 Aug 2017 08:30am EDT 

Aug 1 (Reuters) - Cerus Corp :Cerus announces expanded supply agreement with french national blood service.Cerus corp - signing of two, new, expanded contracts with établissement français du sang for intercept blood system.One contract covers supply of intercept platelet kits.Cerus corp - initial term of platelet kit supply agreement is 2 years with 2 one-year extension options.Other contract is for purchase of additional illuminators to help support roll-out of intercept platelet kits to new regions.  Full Article

Cerus provides update on U.S. Platelet additive solution supply
Wednesday, 7 Jun 2017 08:30am EDT 

June 7 (Reuters) - Cerus Corp ::Cerus provides update on U.S. Platelet additive solution (pas) supply.Cerus Corp - expected Fresenius Kabi pas shortage could be less disruptive to blood center production of intercept platelets than initially anticipated.Cerus Corp - "cautiously optimistic that a future supply shortage for our customers has been mitigated by FDA decision".Cerus - expectation follows decision by FDA to review a recent submission by Fresenius Kabi as a changes being effected in 30 days (cbe-30) supplement.  Full Article

Elk Creek Partners reports 5.17 pct passive stake in Cerus as of May 4 - SEC filing
Monday, 8 May 2017 11:47am EDT 

May 8 (Reuters) - Elk Creek Partners : :Elk Creek Partners reports 5.17 percent passive stake in Cerus Corp as of May 4 - SEC filing.  Full Article

Cerus Corp reports Q1 loss per share $0.18
Wednesday, 3 May 2017 04:01pm EDT 

May 3 (Reuters) - Cerus Corp :Cerus Corporation reports first quarter 2017 results.Q1 loss per share $0.18.Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.Cerus Corp - Product revenue recognized during Q1 of 2017 was $7.0 million compared to $7.6 million during same period in 2016.Cerus Corp - 2017 product revenue guidance to a new range of $43 million to 48 million.  Full Article

BRIEF-Cerus receives IDE approval to initiate phase iii recepi study

* Cerus Corporation receives IDE approval to initiate phase iii recepi study Source text for Eikon: Further company coverage: